KR101277520B1 - （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 - Google Patents

（할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 Download PDF

Info

Publication number
KR101277520B1
KR101277520B1 KR1020077008185A KR20077008185A KR101277520B1 KR 101277520 B1 KR101277520 B1 KR 101277520B1 KR 1020077008185 A KR1020077008185 A KR 1020077008185A KR 20077008185 A KR20077008185 A KR 20077008185A KR 101277520 B1 KR101277520 B1 KR 101277520B1
Authority
KR
South Korea
Prior art keywords
mao
pharmaceutical composition
expressed
ratio
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077008185A
Other languages
English (en)
Korean (ko)
Other versions
KR20070061863A (ko
Inventor
엘레나 바르반티
플로리안 탈레르
카를라 카씨아
루게로 파리엘로
파트리시아 살바티
Original Assignee
뉴론 파마슈티칼즈 에스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴론 파마슈티칼즈 에스. 피. 에이. filed Critical 뉴론 파마슈티칼즈 에스. 피. 에이.
Publication of KR20070061863A publication Critical patent/KR20070061863A/ko
Application granted granted Critical
Publication of KR101277520B1 publication Critical patent/KR101277520B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077008185A 2004-09-10 2005-07-28 （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 Expired - Lifetime KR101277520B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04021525.3 2004-09-10
EP04021525 2004-09-10
PCT/EP2005/008200 WO2006027052A2 (en) 2004-09-10 2005-07-28 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators

Publications (2)

Publication Number Publication Date
KR20070061863A KR20070061863A (ko) 2007-06-14
KR101277520B1 true KR101277520B1 (ko) 2013-06-21

Family

ID=34926488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008185A Expired - Lifetime KR101277520B1 (ko) 2004-09-10 2005-07-28 （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물

Country Status (27)

Country Link
US (2) US20080096965A1 (https=)
EP (1) EP1809271B9 (https=)
JP (1) JP5319920B2 (https=)
KR (1) KR101277520B1 (https=)
CN (1) CN101018546B (https=)
AR (1) AR050638A1 (https=)
AT (1) ATE471147T1 (https=)
AU (1) AU2005282028B2 (https=)
BR (1) BRPI0515154A (https=)
CA (1) CA2577408C (https=)
CY (1) CY1110770T1 (https=)
DE (1) DE602005021907D1 (https=)
DK (1) DK1809271T5 (https=)
ES (1) ES2347581T3 (https=)
HR (1) HRP20100400T1 (https=)
IL (1) IL181445A (https=)
ME (1) ME01801B (https=)
MX (1) MX2007002713A (https=)
NO (1) NO338713B1 (https=)
NZ (1) NZ553970A (https=)
PL (1) PL1809271T3 (https=)
PT (1) PT1809271E (https=)
RS (1) RS51411B (https=)
RU (1) RU2391973C2 (https=)
SI (1) SI1809271T1 (https=)
TW (1) TWI351950B (https=)
WO (1) WO2006027052A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
HUE030233T2 (en) 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
PT2155663T (pt) 2007-06-15 2018-01-16 Newron Pharm Spa Derivados de 2-[2-(fenil)etilamino]alcanamida substituídos e sua utilização como moduladores dos canais de sódio e/ou de cálcio
CA2936209C (en) 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
BRPI0821026A2 (pt) * 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
WO2009109334A1 (en) * 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
US9549967B2 (en) 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
JP5808392B2 (ja) * 2010-04-27 2015-11-10 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
ES2602140T3 (es) 2011-06-27 2017-02-17 Newron Pharmaceuticals S.P.A. Derivados de arilalquilaminocarboxamida fluorados
BR112017007224A2 (pt) 2014-10-08 2018-03-06 Spyryx Biosciences Inc inibidores de canais de sódio, de peptídeo, aperfeiçoados
PT3487839T (pt) 2017-06-20 2021-02-11 Raqualia Pharma Inc Derivados de amida como bloqueadores de nav1.7 e nav1.8

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179661B1 (ko) * 1989-05-25 1999-05-15 비토리노 페라리오 N-페닐알킬 치환된 알파-아미노 카복스아미드 유도체 및 이를 포함하는 약제학적 조성물 및 이의 제조방법
KR20010033706A (ko) * 1997-12-31 2001-04-25 베나티 루카 진통제로서 유용한 알파-아미노아미드 유도체
KR20040034686A (ko) * 2001-09-03 2004-04-28 뉴론 파마슈티칼즈 에스. 피. 에이. 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451062A (en) * 1966-03-16 1969-06-24 Theodore Bradley Disposable examination gown
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3658967A (en) * 1966-06-23 1972-04-25 Ici Ltd Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
CH480308A (de) * 1966-08-11 1969-10-31 Ciba Geigy Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
DD151309A5 (de) * 1979-06-01 1981-10-14 Wellcome Found Verfahren zur herstellung von substituierten aminotriazinen
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
DE3483308D1 (de) * 1983-11-21 1990-10-31 Fujisawa Pharmaceutical Co Semicarbazid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2216515A (en) * 1988-03-04 1989-10-11 Nippon Shinyaku Co Ltd Acylphenol derivatives
RU2070041C1 (ru) * 1988-03-04 1996-12-10 Киргизский государственный медицинский институт Средство для стимуляции лейкопоэза
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5482964A (en) * 1994-10-11 1996-01-09 Warner-Lambert Company Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
KR0147963B1 (ko) * 1995-01-10 1998-08-17 강박광 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
GB9500691D0 (en) * 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US5741818A (en) * 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
US6117841A (en) * 1997-05-30 2000-09-12 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
IT1295423B1 (it) * 1997-10-10 1999-05-12 Medivis S R L Uso della flunarizina nella terapia topica del glaucoma
EP2201945B1 (en) * 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
US6458781B1 (en) * 1998-04-27 2002-10-01 David Thomas Connor Substituted diarylalkyl amides as calcium channel antagonists
SE9801494D0 (sv) * 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
EP1094817A1 (en) * 1998-07-09 2001-05-02 Warner-Lambert Company Compositions comprising gaba analogs and caffeine
WO2000006559A1 (en) * 1998-07-30 2000-02-10 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6472530B1 (en) * 1999-09-22 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
JP2003528104A (ja) * 2000-03-23 2003-09-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド チエピノ［３，２−ｂ］ジヒドロピリジンおよび関連組成物ならびに方法
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
EP1458386B1 (en) * 2001-12-27 2007-04-18 Ortho-McNeil Pharmaceutical, Inc. Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1535908A1 (en) * 2003-11-24 2005-06-01 Newron Pharmaceuticals S.p.A. N-acyl-N'-benzyl-alkylendiamino drivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179661B1 (ko) * 1989-05-25 1999-05-15 비토리노 페라리오 N-페닐알킬 치환된 알파-아미노 카복스아미드 유도체 및 이를 포함하는 약제학적 조성물 및 이의 제조방법
KR20010033706A (ko) * 1997-12-31 2001-04-25 베나티 루카 진통제로서 유용한 알파-아미노아미드 유도체
KR20040034686A (ko) * 2001-09-03 2004-04-28 뉴론 파마슈티칼즈 에스. 피. 에이. 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators

Also Published As

Publication number Publication date
CA2577408C (en) 2013-07-09
CN101018546A (zh) 2007-08-15
MX2007002713A (es) 2007-05-23
NO338713B1 (no) 2016-10-03
KR20070061863A (ko) 2007-06-14
PT1809271E (pt) 2010-08-30
AU2005282028A1 (en) 2006-03-16
DK1809271T3 (da) 2010-09-20
WO2006027052A3 (en) 2006-05-26
EP1809271A2 (en) 2007-07-25
CN101018546B (zh) 2013-06-12
NZ553970A (en) 2010-01-29
JP5319920B2 (ja) 2013-10-16
ES2347581T3 (es) 2010-11-02
SI1809271T1 (sl) 2010-10-29
HK1105359A1 (en) 2008-02-15
AU2005282028A2 (en) 2006-03-16
WO2006027052A2 (en) 2006-03-16
DK1809271T5 (da) 2010-12-06
US20080096965A1 (en) 2008-04-24
US20110184068A1 (en) 2011-07-28
ATE471147T1 (de) 2010-07-15
TWI351950B (en) 2011-11-11
RS51411B (sr) 2011-02-28
DE602005021907D1 (de) 2010-07-29
JP2008512405A (ja) 2008-04-24
CY1110770T1 (el) 2015-06-10
EP1809271B1 (en) 2010-06-16
RU2391973C2 (ru) 2010-06-20
BRPI0515154A (pt) 2008-07-08
RU2007113190A (ru) 2008-10-27
IL181445A0 (en) 2007-07-04
AU2005282028B2 (en) 2011-03-24
TW200612894A (en) 2006-05-01
NO20071792L (no) 2007-06-11
ME01801B (me) 2011-02-28
IL181445A (en) 2014-03-31
HRP20100400T1 (hr) 2010-09-30
CA2577408A1 (en) 2006-03-16
EP1809271B9 (en) 2010-09-22
AR050638A1 (es) 2006-11-08
PL1809271T3 (pl) 2010-10-29

Similar Documents

Publication Publication Date Title
US20110184068A1 (en) Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
JP2008512405A5 (https=)
WO2003057205A2 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
CN1044367C (zh) (S)－α－苯基－2－吡啶乙胺,其制法及含该化合物的组合物
RU2387636C2 (ru) N-ацил-n`-бензилалкилендиаминопроизводные
JP4769194B2 (ja) シクロペンチル誘導体
KR101208390B1 (ko) 3-아미노피롤리돈 유도체
HK1105359B (en) (halobenzyloxy)benzylamino-propanamides as sodium and/or calcium channel selective modulators
HK1097512B (en) Cyclopentyl derivatives
MXPA06005777A (en) Cyclopentyl derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160607

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170609

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190611

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250729

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION